Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IMA-203 |
| Trade Name | |
| Synonyms | IMA203|IMA 203|ACTengine IMA203 |
| Drug Descriptions |
IMA-203 is a preparation of autologous T-cells engineered to express T-cell receptors (TCR) that target tumor-associated antigens, which potentially results in enhanced immune response against tumor cells (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C161831 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| IMA-203 | IMA-203 | 0 | 2 |
| IMA-203 + mRNA-4203 | IMA-203 mRNA-4203 | 0 | 1 |